期刊
NEUROTHERAPEUTICS
卷 12, 期 3, 页码 631-640出版社
SPRINGER
DOI: 10.1007/s13311-015-0353-y
关键词
Rett syndrome; Rare disease; X-linked dominant; MECP2; Clinical trials; Drug targets
资金
- National Institutes of Health (NIH) [NS-065027, HD-074418]
- Rettsyndrome.org
- Rett Syndrome Research Trust
- NIH [HD-061222]
- Civitan International Research Center
Rett syndrome (RTT) is a syndromic autism spectrum disorder caused by loss-of-function mutations in MECP2. The methyl CpG binding protein 2 binds methylcytosine and 5-hydroxymethycytosine at CpG sites in promoter regions of target genes, controlling their transcription by recruiting co-repressors and co-activators. Several preclinical studies in mouse models have identified rational molecular targets for drug therapies aimed at correcting the underlying neural dysfunction. These targeted therapies are increasingly translating into human clinical trials. In this review, we present an overview of RTT and describe the current state of preclinical studies in methyl CpG binding protein 2-based mouse models, as well as current clinical trials in individuals with RTT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据